Chimeric antigen receptors targeting CD79B and CD19
AssigneeThe General Hospital Corporation
InventorMarcela V. Maus
Life of this patent
Estimating the term…
Abstract
Described herein are upfront methods for treating a patient suffering from a cancer. The method includes administering to the patient a therapeutically effective amount of an anti-cancer therapy including a chimeric antigen receptor (CAR) including an extracellular domain including a CD79b-binding domain and a CD19-binding domain, wherein the patient has not been previously treated for the cancer. The invention accordingly also relates to methods of producing and utilizing, e.g., T cells including CARs having an extracellular domain that binds CD79b and CD19.
Claims11
A method for treating a patient suffering from a cancer, the method comprising administering to the patient a therapeutically effective amount of an anti-cancer therapy comprising a chimeric antigen receptor (CAR) comprising an extracellular domain comprising a CD79b-binding domain and a CD19-binding domain, wherein the CAR comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:
- 1, 2, 24, or 25.
Dependencies are inferred from the claim text.